Trials / Completed
CompletedNCT00889525
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Seth Gordhandas Sunderdas Medical College · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma. Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabergoline | Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study. |
Timeline
- Start date
- 2007-11-01
- First posted
- 2009-04-29
- Last updated
- 2009-04-29
Locations
1 site across 1 country: India
Source: ClinicalTrials.gov record NCT00889525. Inclusion in this directory is not an endorsement.